NovaBay Pharmaceuticals, Inc.
NBY
$0.6101
-$0.0081-1.31%
AMEX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 732.84% | 0.00% | 23.53% | 50.68% | 21.76% |
| Total Depreciation and Amortization | -42.11% | 0.00% | -46.93% | 86.46% | 1.05% |
| Total Amortization of Deferred Charges | 766.67% | -97.93% | -53.38% | -25.06% | -27.32% |
| Total Other Non-Cash Items | 858.62% | -495.45% | -92.33% | -83.40% | -25.98% |
| Change in Net Operating Assets | 482.53% | 120.61% | -583.04% | -13.53% | -8.28% |
| Cash from Operations | 1,102.57% | 52.84% | -256.57% | 18.36% | 13.24% |
| Capital Expenditure | -- | 100.00% | 0.00% | 0.00% | 33.33% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | 100.00% | 0.00% | 0.00% | 33.33% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | 100.00% | -27.01% | -7.61% | 17.90% |
| Issuance of Common Stock | -- | -100.00% | 1,173.89% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 100.00% | -405.26% | -116.81% |
| Cash from Financing | -441.60% | -76.07% | 524.59% | 17.59% | -2,196.15% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 2,422.83% | -1,430.77% | 102.43% | 17.98% | -412.55% |